Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Sichuan Kelun-Biotech Biopharmaceutical stock has delivered a very large 3 year gain, yet current valuation checks and market ...

The thing about biotech is that when a stock gets key approvals and smashes its third-phase-trial goals, it can tend to make ...

The company is on the verge of becoming a commercial-stage biotech, with two promising therapies in phase 3 trials.

Replimune stock soars after a FDA advisory committee votes that the company’s study on its skin cancer treatment is ...

El gigante farmacéutico británico AstraZeneca y su rival estadounidense Bristol Myers Squibb (BMS) conversaron sobre una posible fusión que daría lugar a uno de los mayores grupos del sector, con un ...

Fortress Biotech is trading below its cash balance, offering deep value relative to its assets and financial improvements.

Legend Biotech has frequently been at the center of takeover rumors, and the stock regularly spikes on speculation that it has received formal buyout bids. It stands out as one of the most uniquely ...

Biotech remains one of the market's more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.

Biotech is setting up as one of the more interesting risk-on trades heading into the back half of 2026. These three names are ...